newsfilter
← Latest News
PR Newswire·

Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2059 and Leading Targeted Alpha Therapy Platform at AACR Annual Meeting

FPI-2059 induces tumor growth inhibition in colorectal tumor model TEM-1 and EGFRvIII demonstrate potential as TAT targets HAMILTON, ON and BOSTON, April 19, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a